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ABSTRACT Kaposi’s sarcoma-associated herpesvirus (KSHV) is the causative agent of human Kaposi’s sarcoma, a tumor that
arises from endothelial cells, as well as two B cell lymphoproliferative diseases, primary effusion lymphoma and multicentric
Castleman’s disease. KSHV utilizes a variety of mechanisms to evade host immune responses and promote cellular transforma-
tion and growth in order to persist for the life of the host. A viral homolog of human interleukin-6 (hIL-6) named viral
interleukin-6 (vIL-6) is encoded by KSHV and expressed in KSHV-associated cancers. Similar to hIL-6, vIL-6 is secreted, but the
majority of vIL-6 is retained within the endoplasmic reticulum, where it can initiate functional signaling through part of the
interleukin-6 receptor complex. We sought to determine how intracellular vIL-6 modulates the host endothelial cell environ-
ment by analyzing vIL-6’s impact on the endothelial cell transcriptome. vIL-6 significantly altered the expression of many cellu-
lar genes associated with cell migration. In particular, vIL-6 upregulated the host factor carcinoembryonic antigen-related cell
adhesion molecule 1 (CEACAM1) at the protein and message levels. CEACAM1 has been implicated in tumor invasion and me-
tastasis and promotes migration and vascular remodeling in endothelial cells. We report that vIL-6 upregulates CEACAM1 by a
STAT3-dependent mechanism and that CEACAM1 promotes vIL-6-mediated migration. Furthermore, latent and de novo KSHV
infections of endothelial cells also induce CEACAM1 expression. Collectively, our data suggest that vIL-6 modulates endothelial
cell migration by upregulating the expression of cellular factors, including CEACAM1.
IMPORTANCE Kaposi’s sarcoma-associated herpesvirus (KSHV) is linked with the development of three human malignancies,
Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. KSHV expresses many factors that enable
the virus to manipulate the host environment in order to persist and induce disease. The viral interleukin-6 (vIL-6) produced by
KSHV is structurally and functionally homologous to the human cytokine interleukin-6, except that vIL-6 is secreted slowly and
functions primarily from inside the host cell. To investigate the unique intracellular role of vIL-6, we analyzed the impact of
vIL-6 on endothelial cell gene expression. We report that vIL-6 significantly alters the expression of genes associated with cell
movement, including that for CEACAM1. The gene for CEACAM1 was upregulated by vIL-6 and by latent and primary KSHV
infection and promotes vIL-6-mediated endothelial cell migration. This work advances the field’s understanding of vIL-6 func-
tion and its contribution to KSHV pathogenesis.
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Kaposi’s sarcoma-associated herpesvirus (KSHV), also knownas human herpesvirus 8, is the eighth human herpesvirus
identified and is the etiological agent of Kaposi’s sarcoma (KS),
primary effusion lymphoma (PEL), and multicentric Castleman’s
disease (MCD) (1–3). KSHV-associated malignancies typically,
but not always, present in immunosuppressed patients such as
HIV-positive individuals, and because of the high AIDS incidence
in sub-Saharan Africa, KS has become the most common cancer
among African men (4, 5). KSHV is a gammaherpesvirus that has
a double-stranded DNA genome and enveloped virion (6) and is
able to transition between a latent phase and an actively replicat-
ing lytic phase. The virus expresses 80 open reading frames
(ORFs), many of which inhibit various host immune defenses or
promote the growth and transformation of host cells. These strat-
egies allow KSHV to persist for the life of the host and induce
pathogenesis in immunocompromised individuals.
The KSHV protein expressed by ORF K2 is known as viral
interleukin-6 (vIL-6) because of its sequence and structural simi-
larity to the cytokine, human interleukin-6 (hIL-6) (7–9). vIL-6 is
expressed at low but functional levels during viral latency and
becomes highly upregulated during lytic induction (10–12). Im-
portantly, vIL-6 can be detected in the serum and/or tissue of
patients with KSHV-associated malignancies, and in those with
MCD, higher vIL-6 levels correlate with a poorer prognosis (13–
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15). vIL-6 expression is transforming in NIH 3T3 cells (16), and a
transgenic mouse expressing vIL-6 developed MCD-like disease
(17). vIL-6 has been shown to drive the expression of vascular
endothelial growth factor (VEGF) and induce hematopoiesis and
angiogenesis (16). Additionally, vIL-6 drives the expression of
hIL-6 (16, 18) and promotes cell migration and survival, as well as
activation of hIL-6-dependent signaling cascades such as the JAK/
STAT, mitogen-activated protein kinase (MAPK), and phospha-
tidylinositol 3-kinase (PI3K) pathways (19–23).
Despite their structural similarities, vIL-6 differs from hIL-6 in
that vIL-6 is secreted from the cell more slowly and accumulates in
the endoplasmic reticulum (ER), where it can signal intracellu-
larly through the gp130 subunit of the IL-6 receptor (IL-6R) (12,
24). To better understand how vIL-6 interacts with the host cell,
we previously identified a cellular protein called hypoxia-
upregulated protein 1 (HYOU1) that plays a critical role in vIL-6-
mediated signaling, survival, and migration (25). Two other host
proteins, VKORC1v2 and calnexin, have also been identified as
vIL-6-interacting partners, and these cellular proteins appear to
play a role in vIL-6-mediated cell survival and vIL-6 folding and
intracellular retention, respectively (12, 26, 27).
We wanted to investigate how intracellular expression of vIL-6
impacts the global transcriptional profile of endothelial cells since
these cells can be infected with KSHV in vivo and are the cells that
drive the development of KS lesions (28, 29). To explore the im-
pact of intracellular vIL-6 on gene expression, we performed mi-
croarray analysis of endothelial cells stably expressing vIL-6. We
identified some genes known to be upregulated by vIL-6 (16, 18,
25) and many genes that were previously not known to be upregu-
lated by vIL-6. In particular, vIL-6 increased the expression of a
number of genes significantly associated with cell invasion and
endothelial cell movement and chemotaxis, including the gene
for carcinoembryonic antigen-related adhesion molecule 1
(CEACAM1).
CEACAM1 (also known as CD66a and biliary glycoprotein) is
a transmembrane adhesion molecule that is expressed in a num-
ber of different cell types, including endothelial, epithelial, and
hematopoietic cells (30). Although some earlier studies reported
that CEACAM1 expression decreases in colorectal cancer (31),
more recent clinical studies and profiling in a wide variety of hu-
man tumors, including colon (32), melanoma (33–35), lung (36),
pancreas (37), bladder (38, 39), and thyroid (40) cancers, found
that high levels of CEACAM1 are expressed on tumor cells and
that CEACAM1 expression directly correlates with a poor prog-
nosis and tumor metastasis. CEACAM1 may also play a role in
damping the immune response to cancer, which may contribute
to cancer progression (41). In addition, CEACAM1 has consis-
tently been shown to augment angiogenesis, increase the migra-
tion of endothelial cells, and to induce vascular remodeling (42–
46). Interestingly, human cytomegalovirus (hCMV) encodes a
viral homolog of CEACAM1 that has also been shown to be im-
portant in promoting angiogenesis (47).
We found that expression of vIL-6 and de novo and latent
KSHV infection upregulate CEACAM1 transcript and protein lev-
els in endothelial cells. We determined that CEACAM1 expression
is at least partially driven by vIL-6-mediated STAT3 signaling.
Finally, we found that knockdown of CEACAM1 abrogated the
vIL-6-mediated migration of endothelial cells, indicating that
CEACAM1 may play a critical role in promoting invasion of
KSHV-infected endothelial cells.
RESULTS
Intracellular vIL-6 induces expression of genes involved in cell
migration. To investigate the effect of intracellular vIL-6 on the
cellular transcriptome of human endothelial cells, an Agilent 4 
44K human microarray was prepared in duplicate with RNA har-
vested from human telomerase reverse transcriptase (hTERT)-
immortalized human umbilical vein endothelial cells (hTERT-
HUVEC) expressing the empty vector (EV) or FLAG-tagged vIL-6
(vIL-6). Cellular genes that were upregulated 10-fold in vIL-6-
expressing endothelial cells compared to EV-expressing cells are
shown in Table 1. Cellular genes that were downregulated 10-
fold in vIL-6-expressing endothelial cells compared to EV-
expressing cells are shown in Table 2. Ingenuity pathway analysis
(IPA) software was utilized to identify major disease pathways
associated with the altered host gene expression that was observed
with vIL-6 expression. IPA analysis revealed that KSHV vIL-6 sig-
nificantly impacted pathways associated with cancer, cellular
movement, and cell-cell signaling and interaction (Fig. 1A). We
further investigated vIL-6’s impact on genes associated with cel-
lular movement since we previously reported that vIL-6 can pro-
mote the migration of endothelial cells (25). We found that there
were a significant number of genes associated with endothelial cell
movement, chemotaxis, and cell invasion that were altered by
vIL-6 expression (Fig. 1B). Furthermore, based on how vIL-6 in-
fluenced the expression of these migration-associated genes, IPA
predicted that vIL-6 should induce cellular migration, thus con-
firming our previous findings (25). In addition to the identifica-
tion of many previously unidentified vIL-6 target genes, we also
found some genes known to be upregulated by vIL-6, including
those for chemokine (C-C motif) ligand 2 (CCL2) (25) and VEGF
(16), which were also identified in the cell movement subpath-
ways, and hIL-6 (18) (Fig. 1B and C).
The gene for CEACAM1, which is associated with cellular
movement and invasion, was upregulated nearly 12-fold in vIL-6-
expressing endothelial cells (Fig. 1B; Table 1). We confirmed that
expression of FLAG-tagged vIL-6 in endothelial cells significantly
upregulates the CEACAM1 mRNA message compared to that of
the EV by real-time quantitative PCR (qPCR) (Fig. 2A). vIL-6
expression also upregulated the CEACAM1 protein in endothelial
cells (Fig. 2B). CEACAM1 has numerous isoforms that arise
from alternative splicing of the transcript (Fig. 2C) (30). These
isoforms exist in three general categories: secreted CEACAM1 that
lacks a transmembrane domain, long isoforms of CEACAM1
(CEACAM1-L) that contain an intracellular immunotyrosine in-
hibitory motif (ITIM) that can modulate downstream signaling,
and short isoforms (CEACAM1-S) that lack this intracellular sig-
naling domain on the cytoplasmic tail. The ratios of each isoform
can also differ between cell types and dictate the outcome of
CEACAM1 expression (48, 49). Larger amounts of CEACAM1-L
in cancer correlate with metastatic spread and shorter patient sur-
vival (50, 51). We speculated that the two species of CEACAM1
visible by Western blotting represent the long and short isoforms
of this protein. We performed additional qPCR experiments with
primers specific to the nucleotides encoding the ITIM region of
the long isoform, CECAM1-L. We found that vIL-6 induces not
only the total CEACAM1 transcript but also CEACAM1-L
(Fig. 2D).
vIL-6 upregulates CEACAM1 through activation of STAT3.
vIL-6 is a potent activator of STAT3 (12, 23, 25, 52), so we sought
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to determine if vIL-6-mediated STAT3 signaling is the mechanism
by which vIL-6 upregulates CEACAM1 mRNA and protein. S3I-
201 is a small molecule that inhibits the ability of STAT3 to
dimerize and become activated (53). Siddiquee et al. reported that
S3I-201 has a preference for STAT3 and that at concentrations
that inhibit STAT3, S3I-201 has very little effect on STAT1 and
STAT5 (53). Hence, in our experiments, we used a concentration
of S3I-201 (60 to 75 M) that would inhibit STAT3 but not affect
STAT1 (53). We treated endothelial cells stably expressing the EV
or FLAG-tagged vIL-6 with 60 M S3I-201 or a vehicle control
(dimethyl sulfoxide [DMSO]) for 48 h. RNA was harvested, and
qPCR was performed. In vehicle-treated cells, CEACAM1 levels
were much higher in vIL-6-expressing cells than in EV-expressing
cells; however, treatment with S3I-201 greatly reduced CEACAM1
transcript levels in vIL-6-expressing cells (Fig. 3A). Furthermore,
treatment with S3I-201 produced significantly lower CEACAM1
protein levels in vIL-6-expressing cells than in vehicle control-
treated cells (Fig. 3B). Western blot assays confirmed that Tyr705
phosphorylation of STAT3 was increased by expression of vIL-6
and that treatment with S3I-201 reduced STAT3 phosphoryla-
tion, as expected (Fig. 3B). These data suggest that STAT3 signal-
ing may play a role in vIL-6-mediated upregulation of CEACAM1.
hIL-6 does not influence CEACAM1 expression. Since vIL-6
and hIL-6 show homology, we wanted to determine if hIL-6, alone
or in combination with vIL-6, can drive CEACAM1 expression.
We treated endothelial cells stably expressing the EV or FLAG-
tagged vIL-6 with recombinant hIL-6 at 0, 100, or 250 ng/ml for
48 h. RNA and lysates were harvested from these cells, and West-
ern blotting and qPCR assays were performed. Phosphorylation of
STAT3 Tyr705 was induced in EV-expressing cells upon hIL-6
treatment, although not nearly to the high levels seen in vIL-6-
expressing cells (Fig. 3D). Interestingly, exogenous hIL-6 did not
increase CEACAM1 expression in either EV- or vIL-6-expressing
cells at either the transcript (Fig. 3C) or the protein (Fig. 3D) level.
Cells were also treated with hIL-6 at 100 ng/ml for 72 h, and sim-
ilar trends were seen (data not shown). This suggests that intracel-
TABLE 1 Endothelial cell gene products upregulated by vIL-6 10-fold
Gene product GenBank accession no. Fold change (vIL-6/EV) Gene product GenBank accession no. Fold change (vIL-6/EV)
LIMCH1 NM_014988 138.70 GPC6 NM_005708 19.01
TPBG NM_006670 128.84 FOXJ1 NM_001454 18.81
SERPINB3 NM_006919 92.25 MAP3K8 AB209539 17.80
CH25H NM_003956 60.99 CALCA NM_001033953 16.95
C1S NM_001734 60.01 ABCA1 NM_005502 16.48
SERPINB4 NM_002974 56.39 MTUS1 NM_001001925 16.02
SYTL2 NM_206927 50.09 CFI NM_000204 16.01
BTBD17 NM_001080466 47.79 PDPN NM_198389 14.83
DCN NM_001920 44.61 ABCA1 NM_005502 14.74
FAM55B NM_182495 42.13 SPP1 NM_001040058 13.56
CCL2 NM_002982 38.04 KLRD1 NM_002262 13.40
GPR116 NM_001098518 35.30 RAPGEF4 NM_007023 13.14
PCDH7 NM_002589 33.17 C1R NM_001733 12.97
SERPINA3 NM_001085 28.93 GPR68 NM_003485 12.94
LRRC4C NM_020929 28.23 FAM55B NM_182495 12.78
BDKRB2 NM_000623 27.94 PYGL NM_002863 12.67
COL4A4 NM_000092 25.62 CARKD NM_001242881 12.58
PTN NM_002825 25.37 EGLN3 NM_022073 12.55
TNIP3 NM_024873 25.06 SOCS3 NM_003955 11.94
SPARCL1 NM_004684 24.47 CEACAM1 NM_001712 11.76
JAK3 NM_000215 22.73 CDH11 NM_001797 11.75
KIF19 NM_153209 22.19 KCNAB1 NM_003471 11.69
ARHGAP24 AK130576 21.25 LINC00305 NR_027245 11.60
LGI2 NM_018176 21.09 LOC120824 NM_001206625 11.23
IL1R1 NM_000877 20.64 TRIM53P NR_028346 11.15
UMODL1 NM_173568 20.33 HLA-DRB5 NM_002125 10.80
RDH16 NM_003708 20.29 FGL1 NM_201553 10.74
LIMCH1 NM_014988 20.11 IL33 NM_033439 10.46
GPR116 NM_001098518 19.86 FPR3 NM_002030 10.36
FOXQ1 NM_033260 19.75 TM4SF5 NM_003963 10.00
KRT6A NM_005554 19.44
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lular vIL-6 is unique in its ability to drive CEACAM1 expression in
endothelial cells, despite its similarities to hIL-6.
CEACAM1 is required for migration of vIL-6-expressing en-
dothelial cells. Based on CEACAM1’s proposed role in the inva-
sion and metastasis of a number of cancers (35, 39, 40), we wanted
to determine if it plays a role in the biological function of vIL-6.
We transfected EV- or vIL-6-expressing stable endothelial cells
with a non-targeting control (NTC) or CEACAM1-targeting
small interfering RNA (siRNA) and plated the cells on dishes
coated with collagen IV as previously described (40). At 40 h post-
transfection, cells were serum starved for 8 h. Monolayers were
scratched with a P200 pipette tip, and triplicate images of each
scratch were captured at 0, 15, and 24 h post-scratch (Fig. 4A).
ImageJ software was utilized to trace the remaining area of each
scratch and quantify the size of the area remaining compared to
that of each scratch at 0 h (Fig. 4B). vIL-6-expressing endothelial
FIG 1 vIL-6 modulates the expression of host genes associated with cell movement. (A) RNA was harvested from endothelial cells (hTERT-HUVEC) expressing
the EV or FLAG-tagged vIL-6 and used in an Agilent 4  44K human microarray. Gene fold changes were imported into IPA, and the top vIL-6-associated
diseases and biological functions were analyzed. (B) Top modulated genes from selected cell movement-associated subpathways from IPA. Fold change values
represent vIL-6-expressing cells compared to EV-expressing cells and the predicted cell movement phenotype based on IPA analysis. P values calculated by IPA
represent how significantly vIL-6 expression impacts cellular genes associated with that particular subpathway. (C) Microarray data for genes known to be
upregulated by vIL-6: VEGF, CCL2, and hIL-6.
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cells rapidly migrated and closed the scratch much more quickly
than EV-expressing cells; however, knockdown of CEACAM1 re-
duced the ability of vIL-6-expressing cells to close the gap as
quickly. Following completion of the assay, lysates were harvested
for SDS-PAGE and Western blotting to confirm CEACAM1
knockdown (Fig. 4C). Our results suggest that CEACAM1 plays a
role in the vIL-6-mediated migration of endothelial cells.
CEACAM1 is upregulated by KSHV infection in multiple cell
types. We next wanted to determine if CEACAM1 is upregulated
following primary KSHV infection. vIL-6 is expressed at low but
functional levels during latency (12) and is highly upregulated
during lytic infection or lytic reactivation (10, 11). We first inves-
tigated if de novo infection of primary HUVEC with recombinant
KSHV expressing green fluorescent protein (GFP) (54) could in-
duce CEACAM1 upregulation. Upon KSHV infection of endothe-
lial cells, the virus undergoes several rounds of lytic infection be-
fore establishing latency (55). At 30 h postinfection, almost 100%
of the cells receiving KSHV were GFP positive, whereas the mock-
infected control contained no detectable GFP-positive cells
(Fig. 5A). RNA and lysates were harvested and analyzed by qPCR
assay and Western blotting, respectively. Ample vIL-6 transcript
was detected in addition to another viral lytic transcript, ORF57,
confirming KSHV infection of these cells (Fig. 5B). The
CEACAM1 message level was upregulated 6-fold in KSHV-
infected cells compared to that in the mock-infected control
(Fig. 5C), and we were also able to detect significant upregulation
of CEACAM1 protein in infected cells by Western blotting
(Fig. 5D).
We next analyzed CEACAM1 message and protein levels in
uninfected endothelial cells (hTERT-HUVEC) and latently in-
fected KSHV-HUVEC (56). We found that CEACAM1 was also
upregulated at the message and protein levels in the latent KSHV-
HUVEC (Fig. 5E and F).
To test another physiologically relevant cell type for the impact
FIG 2 vIL-6 upregulates CEACAM1 in endothelial cells. (A) cDNA was generated from hTERT-HUVEC stably expressing the EV or FLAG-tagged vIL-6 and
used for qPCR analysis of the total CEACAM1 message. (B) Lysates were harvested from hTERT-HUVEC stably expressing the EV or FLAG-tagged vIL-6.
SDS-PAGE and Western blotting of the proteins indicated were performed. (C) CEACAM1 exists in a number of transmembrane and secreted isoforms that
differ in the number and type of extracellular immunoglobulin domains and the presence or absence of a transmembrane domain, a long cytoplasmic tail, and
Alu repeats (A). (D) cDNA was generated from endothelial cells stably expressing the EV or FLAG-tagged vIL-6 and used for qPCR analysis of the total
CEACAM1 message and the CEACAM1-L message.
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of KSHV infection on CEACAM1 expression, we used a latently
infected PEL cell line, BCBL1. TREx BCBL1-RTA cells stably ex-
press a doxycycline-inducible RTA expression plasmid and are
reactivated within 24 h of doxycycline addition as previously de-
scribed (57). The control cell line, TREx BCBL1, expresses a
doxycycline-inducible EV and maintains a latent infection upon
doxycycline addition. These two cell lines were treated with
1 g/ml doxycycline for 24 h prior to harvest of RNA and lysates.
Interestingly, we found by Western blotting that reactivation of
these cells caused a large increase in the level of a single discrete
species of CEACAM1 compared to that in latently infected cells
(Fig. 5H). We performed a qPCR assay of RNA harvested from
TREx BCBL1 cells and noted that the total CEACAM1 message
was upregulated in reactivated cells (Fig. 5G). We also quantified
the long isoform of CEACAM1 with an ITIM-specific primer set
and found that the long isoforms of CEACAM1 were not dramat-
ically upregulated in lytically reactivated cells compared to latently
infected cells, although total CEACAM1 was still highly increased
in lytic cells. Collectively, these data suggest that CEACAM1 ex-
pression is increased during both primary and latent KSHV infec-
tions and in the context of reactivation in multiple physiologically
relevant cell types.
DISCUSSION
KSHV is the causative agent of the human malignancies KS, PEL,
and MCD. PEL is a non-Hodgkin lymphoma that consists of an
expansion of latently infected B cells in the pleural or pericardial
cavities (58). The plasmablastic variant of MCD is associated with
KSHV infection, and this tumor results from an abnormal prolif-
eration of plasmablasts (59). KS is a highly vascularized tumor that
arises from KSHV-infected endothelial cells, and all KS tumor
cells harbor the virus (28, 60). KSHV and other human herpesvi-
ruses persist for the life of the host. To accomplish this, herpesvi-
ruses must intricately modulate their surroundings to create a
favorable environment for propagation. The KSHV genome en-
codes an arsenal of proteins and small RNAs that help the virus
persist via a number of mechanisms, including direct and indirect
evasion of the host immune system, modulation of host cell sig-
naling, and mimicry of host chemokines and cytokines. An exam-
ple of mimicry of host proteins is the KSHV protein vIL-6, which
is a homolog of hIL-6.
vIL-6 and elevated hIL-6 are detectable in all KSHV-associated
malignancies (14, 61–63), and these two cytokines likely work in a
synergistic manner to create a proinflammatory environment that
promotes disease. Despite their similarities, hIL-6 and vIL-6 have
differential requirements for signaling through the IL-6R; the
gp80 and gp130 IL-6R subunits are essential for hIL-6 signaling,
but vIL-6 can signal through gp130 in the absence of gp80 (13, 64).
Since gp80 is predominantly on the cell membrane, this limits
hIL-6 to extracellular signaling, whereas vIL-6 is able to signal
intracellularly through ER-embedded gp130 (12). Furthermore,
hIL-6 is rapidly secreted from cells but vIL-6 is primarily retained
within the ER (24). On the basis of its unique intracellular local-
ization and signaling capabilities, we wanted to determine how
FIG 3 vIL-6, but not hIL-6, upregulates CEACAM1 in a STAT-3-dependent manner. (A) cDNA was generated from hTERT-HUVEC stably expressing the EV
or FLAG-tagged vIL-6 that were treated with DMSO or 60 M S3I-201 for 48 h in medium containing 2% serum. A qPCR assay was performed to assess total
CEACAM1 message levels. (B) Lysates were harvested from endothelial cells stably expressing the EV or FLAG-tagged vIL-6 that were treated with DMSO or
75 M S3I-201 for 72 h in medium containing 10% serum. SDS-PAGE and Western blotting of the proteins indicated were performed. (C) hTERT-HUVEC
stably expressing the EV or FLAG-tagged vIL-6 were treated with exogenous hIL-6 for 48 h. cDNA was generated and analyzed for the total CEACAM1 message
by qPCR. (D) Endothelial cells stably expressing the EV or FLAG-tagged vIL-6 were treated with exogenous hIL-6 for 48 h. Lysates were harvested and subjected
to SDS-PAGE and Western blotting for the proteins indicated.
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vIL-6 modulates the intracellular host environment to promote its
function.
We previously reported that vIL-6 mediated the migration of
endothelial cells in a manner that was partly dependent on
HYOU1-facilitated expression of the host chemokine CCL2 (25).
We speculated that vIL-6 may influence the expression of a num-
ber of additional cellular genes to promote vIL-6-mediated bio-
logical processes such as endothelial cell chemotaxis and angio-
genesis. A previous study analyzed the impact of vIL-6 on the
expression of several hundred cellular genes in a hepatoma cell
line; however, bacterium-derived vIL-6 was utilized and only a
limited number of transcripts were analyzed (22). To be fully
functional, vIL-6 requires glycosylation derived from mammalian
cell machinery (65), and it is now known that vIL-6 functions
intracellularly (12, 24). The impact of intracellular vIL-6 expres-
sion specifically on the endothelial cell transcriptome is a previ-
ously unexplored area, and endothelial cells are extremely relevant
to KSHV infection since these cells are infected in vivo and give rise
to KS (28, 29).
We performed a human microarray analysis of endothelial
cells stably expressing KSHV IL-6. Our data confirmed previous
reports that vIL-6 upregulates several host genes, e.g., CCL2 (25),
VEGF (16), and hIL-6 (18). We also found that vIL-6 expression
altered genes associated with endothelial cell movement and che-
motaxis and cell invasion. One gene, CEACAM1, was highly up-
regulated by vIL-6 expression at both the message and protein
FIG 4 CEACAM1 facilitates vIL-6-mediated endothelial cell migration. (A) hTERT-HUVEC stably expressing the EV or FLAG-tagged vIL-6 were plated on
collagen IV-coated plates. Cells were transfected with 60 nM non-targeting or CEACAM1-targeting siRNA for 40 h. Cells were serum starved for 8 h, and the
monolayers were then scratched with a P200 pipette tip. Bright-field images were obtained at 40 magnification with a Nikon Eclipse Ti inverted microscope at
0, 15, and 24 h postscratching. Three images of each individual scratch were taken, and representative images are shown. (B) Scratch assays were quantified with
ImageJ software. The starting scratch area was determined and assigned a value of 1, and at subsequent time points, scratch areas were divided by the original area
size to normalize for variation in the original size of each scratch. Three images and measurements of each scratch were taken at each time point and averaged,
and the values and error bars on the graph are averages of two independent experiments. (C) After the 24-h scratch assay time point, cell lysates were harvested
and subjected to SDS-PAGE and Western blotting for the proteins indicated to confirm CEACAM1 siRNA knockdown.
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levels. CEACAM1 is an adhesion protein that is implicated in a
number of human cancers and can promote angiogenesis, migra-
tion, and vascular remodeling in endothelial cells (42–46). Be-
cause KS is a highly angiogenic tumor, we wanted to investigate
the induction of CEACAM1 expression by vIL-6. Furthermore,
CEACAM1 and a CEACAM1 homolog have been shown to con-
tribute to the pathogenesis of other herpesviruses, but the role of
CEACAM1 during KSHV infection has not yet been investigated
(47, 66, 67).
We sought to determine the mechanism by which vIL-6 medi-
ates the increase in CEACAM1 transcription. It has been previ-
ously shown that knockout of STAT3 can reduce CEACAM1 ex-
pression in APCmin mice (68), and vIL-6 is a known inducer of
STAT3 signaling (12, 23, 25, 52). Inhibition of STAT3 activity with
FIG 5 CEACAM1 is upregulated during de novo and latent KSHV infection of endothelial cells and during reactivation in PEL. (A) PBS (mock) or 150 l of
purified KSHV was added to primary HUVEC in the absence of serum, followed by spinoculation. Eighteen hours later, 10% serum was added and at 30 h
post-infection, bright-field and GFP images at 100 magnification were obtained with a Nikon Eclipse Ti inverted microscope. (B) RNA was harvested, and
cDNA was generated from mock- and KSHV-infected primary HUVEC at 30 h postinfection. A qPCR assay was performed for the lytic transcripts vIL-6 and
ORF57 and total CEACAM1 (C). (D) Lysates were harvested from mock- and KSHV-infected primary HUVEC at 30 h postinfection and subjected to SDS-PAGE
and Western blotting for the proteins indicated. (E) RNA was harvested, and cDNA was generated from hTERT-HUVEC left uninfected or latently infected with
KSHV. A qPCR assay for total CEACAM1 was performed. (F) Lysates were harvested from hTERT-HUVEC left uninfected as well as latently infected with KSHV.
Lysates were subjected to SDS-PAGE and Western blotting for the proteins indicated. (G) TREx-BCBL1 and TREx-BCBL1-RTA cells were treated with 1 g/ml
doxycycline for 24 h. RNA was harvested, and cDNA was generated. A qPCR assay was performed to analyze total CEACAM1 and CEACAM1-L levels. (H)
TREx-BCBL1 and TREx-BCBL1-RTA were treated with 1 g/ml doxycycline for 24 h. Lysates were harvested and resolved by SDS-PAGE, followed by Western
blotting for the proteins indicated.
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S3I-201 reduced the CEACAM1 message and protein levels in
vIL-6-expressing endothelial cells. Interestingly, hIL-6 did not up-
regulate CEACAM1 despite its known ability to activate STAT3.
There are several possibilities that could explain this. In our ex-
perimental system, exogenously applied hIL-6 activates STAT3 to
a lesser degree than intracellularly expressed vIL-6, so it is possible
that hIL-6-induced STAT3 activity is not adequate to impact
CEACAM1 expression. Another possibility is that vIL-6 is induc-
ing a unique intracellular pathway directly through gp130 in the
ER that is capable of upregulating CEACAM1. Regardless of
whether hIL-6 is expressed in cells or is added exogenously to the
medium, hIL-6 can only signal extracellularly from gp80-
containing IL-6R complexes found exclusively on the plasma
membrane, and hIL-6 is secreted rapidly, so it does not reside in
the ER like vIL-6. Therefore, it is possible that vIL-6 can activate an
intracellular mechanism from the ER to which hIL-6 does not
have access.
Since CEACAM1 can promote the movement and invasive ca-
pability of endothelial cells (39, 43), we investigated whether vIL-
6-mediated upregulation of CEACAM1 plays a role in cell move-
ment. In the presence of CEACAM1, vIL-6-expressing endothelial
cells migrated rapidly, but knockdown of CEACAM1 abrogated
the ability of these cells to migrate. Knockdown of CEACAM1 in
EV-expressing endothelial cells also reduced migration to a small
degree, which is expected since CEACAM1 is known to affect cell
migration outside the context of vIL-6 (40). These data suggest a
significant biological function of vIL-6 through its ability to up-
regulate CEACAM1 expression to induce increased migration of
endothelial cells.
Previous microarray studies of immortalized dermal micro-
vascular endothelial cells infected with KSHV also reported that
the gene for CEACAM1 was one of multiple genes affected by
KSHV infection (69). Furthermore, CEACAM1 was found to be
upregulated in the lungs of mice infected with the murine gam-
maherpesvirus MHV68 (66, 67). In the present study, we found
that both KSHV latent and de novo infection of endothelial cells
upregulated CEACAM1 expression compared to that in unin-
fected cells, and reactivation of PEL also resulted in increased
CEACAM1 expression. It was recently shown that CEACAM1 ex-
pression is important for the survival of naive B cells and for the
proliferation of activated B cells (70), so KSHV’s induction of
CEACAM1 expression in PEL may be a mechanism by which the
virus promotes the survival of infected B cells in PEL and/or MCD.
In endothelial cells, however, we speculate that vIL-6’s upregula-
tion of the long isoforms of CEACAM1 contributes to the ability
of these infected cells to promote vascular remodeling, migration,
and invasion, which may contribute to the pathogenesis of KS.
We have proposed a model in which intracellular vIL-6 can
promote the function of CEACAM1 to drive cell migration and
pathogenesis (Fig. 6). Intracellular vIL-6 expression activates
STAT3 signaling, which can upregulate CEACAM1 expression
(46). The long isoform of CEACAM1 is expressed on the cell
membrane and can be phosphorylated by receptor tyrosine ki-
nases and tyrosine kinases (TKs) (20, 30). Phosphorylated
CEACAM1-L is thought to promote cell migration by associating
with the integrin regulator talin and by decreasing the activation
of focal adhesion kinase to disrupt integrin function and increase
cell motility (43). Activated CEACAM1 also interacts directly with
components of the cytoskeleton, including actin, myosin, and tro-
pomyosin, which is thought to be a mechanism by which
CEACAM1 influences migration (71, 72). Activated CEACAM1
also interacts with SHP-1/2 phosphatases and/or other TKs, such
as Src, which can stimulate or inhibit a number of downstream
signaling pathways, depending on the molecular makeup of the
FIG 6 Model of CEACAM1’s contribution to endothelial cell migration and pathogenesis in the context of vIL-6 expression. FAK, focal adhesion kinase. P
indicates phosphorylation.
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signaling complex (73). How this signaling further drives migra-
tion and angiogenesis in endothelial cells is unknown, but on the
basis of the known mechanisms of CEACAM1 function, we spec-
ulate that it plays a significant role in promoting the angiogenic
and metastatic capabilities of KS cells.
Collectively, our data have uncovered many previously un-
identified cellular genes whose expression is changed when vIL-6
is expressed in endothelial cells. We have also identified a novel
host protein, CEACAM1, induced by KSHV vIL-6, as well as in the
context of latent and de novo KSHV infection in endothelial cells
and during reactivation in PEL cells. Based on CEACAM1’s estab-
lished roles in angiogenesis, vascular remodeling, cell migration,
and cancer metastasis, vIL-6-induced CEACAM1 may be a very
important player in promoting KSHV-associated pathogenesis,
particularly for endothelial-cell-derived KS. Our results further
elucidate the function of intracellular vIL-6 in KSHV biology.
MATERIALS AND METHODS
Cell culture, generation of stable cell lines, and KSHV infection.
hTERT-HUVEC and primary HUVEC were grown in EBM-2 (Lonza)
with the EBM-2 bullet supplement (Lonza) as previously described (56,
74). TREx BCBL1 and TREx BCBL1-RTA PEL cells (57) were kindly pro-
vided by Jae Jung’s lab and grown in RPMI 1640 medium (Corning)
containing Tet System Approved FBS (Clontech) and 20 M hygromycin
B (Roche). All media were supplemented with 10% heat-inactivated fetal
bovine serum, 1% penicillin-streptomycin, and 1% L-glutamine. hTERT-
HUVEC stably expressing the EV or FLAG-tagged vIL-6 were described
previously (25). TREx-BCBL1 cells were reactivated by supplementing
medium with 1 g/ml doxycycline for 24 to 30 h. The production of
purified KSHV particles (75) and KSHV-infected HUVEC (56) was de-
scribed previously (also see Text S1 in the supplemental material).
Plasmids, siRNAs, and reagents. The pcDNA3.1-vIL-6-FLAG plas-
mid and the lentiviral vIL-6-FLAG construct were previously described
(25). The non-targeting control (NTC) siRNA duplex (D001810-01) was
purchased from Dharmacon. A CEACAM1-targeting Stealth siRNA du-
plex was purchased from Life Technologies (HSS101005). All lentiviruses
were produced with the ViraPower Lentiviral Expression System (Life
Technologies). The S3I-201 STAT3 inhibitor (Selleck Chem) was dis-
solved in DMSO (Sigma) and used at a concentration of 60 to 75 M in
medium with 2% serum for 48 to 72 h. Recombinant hIL-6 (PeproTech)
was resuspended in distilled deionized water and used at a concentration
of 100 or 250 ng/ml. For the Western blotting protocol used and the
antibodies used for blotting, see Text S1 in the supplemental material.
Microarray analysis. RNA was harvested from hTERT-HUVEC sta-
bly expressing the EV or vIL-6-FLAG with TRIzol and checked for quality
with an Agilent Bioanalyzer. One microgram of RNA was submitted to
MOgene for use with the 4  44K human microarray (Agilent). Samples
were run in duplicate with Cy3 and Cy5 dyes switched for each sample to
correct for any fluorescence dye bias. Fold changes for each gene were
calculated. For the full array data and a description of the analysis param-
eters used for IPA, see Text S1 in the supplemental material.
RNA isolation and real-time qPCR. Cells were washed in cold
phosphate-buffered saline (PBS) and resuspended in TRIzol (Life Tech-
nologies), and RNA was harvested in accordance with the manufacturer’s
instructions. To generate cDNA, 1 g of RNA was treated with amplifi-
cation grade DNase I (Invitrogen) and then reverse transcribed with Su-
perscript III reverse transcriptase (Invitrogen) and oligo(dT) primers
(Invitrogen). A qPCR assay was performed with an Advanced Biotechnol-
ogies 7300 instrument with cDNA as the template in SYBR green PCR
master mix (Bio-Rad). For the sequences of the primers used, see
Text S1 in the supplemental material. GAPDH was used as an endogenous
control. PCRs were run in triplicate.
Migration assay. hTERT-HUVEC expressing the EV or FLAG-tagged
vIL-6 were seeded at 0.9  105 per well of a six-well dish coated with
collagen IV (Corning Biocoat) since collagen IV is a known adhesion
substrate of CEACAM1 (40). The following day, cells were transfected
with 60 nM of an NTC or CEACAM1-targeting siRNA with Lipo-
fectamine RNAiMAX in accordance with the manufacturer’s instructions.
The medium was replaced 24 h post-transfection, and at 40 h post-
transfection, cells were serum starved for 8 h. Monolayers were then
scratched with a P200 pipette tip and bright-field images were obtained at
0, 15, and 24 h post-scratch at 40 magnification with a Nikon Eclipse Ti
inverted microscope. Following the assay, cells were harvested in lysis
buffer and analyzed by SDS-PAGE and Western blotting to test
CEACAM1 knockdown efficiency. Scratch closure was quantified with
ImageJ software (NIH) (76).
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